This page is no longer being updated and remains online for informational and historical purposes only. The information is accurate as of the last page update.
For questions about page contents, contact the Communications Division.
With more than 20 years experience in the pharmaceutical industry and head of the oncology business unit of GlaxoSmithKline, Kevin G. Lokay '78 was recently appointed to the board of directors of Cytogen Corporation.
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and health care companies. Lokay spent more than three years with SmithKline Beecham as vice president and director, oncology and specialty products. His experience also includes 16 years with Merck & Co. Inc., where he was vice president, worldwide sales, marketing, and development for its vaccine division.
Lokay, an economics and business graduate, holds an M.B.A. from Krannert School of Management, Purdue University.
Cytogen Corporation is a biopharmaceutical company based in Princeton, N.J.